pentoxifylline has been researched along with Acquired Immune Deficiency Syndrome in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since an AIDS Clinical Trial Group study suggested that pentoxifylline (400 mg thrice daily) is safe in AIDS patients and decreases TNF mRNA levels in peripheral blood mononuclear cells (PBMC), a second cohort received 800 mg thrice daily for 8 weeks." | 2.68 | High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. ( Ahlers, CM; Chapman, B; Dando, S; Dezube, BJ; Flexner, C; Korvick, JA; Lederman, MM; Mattiacci, MR; Spritzler, JG; Zhang, L, 1995) |
| " PTX in a dosage of 1." | 1.30 | The maximal tolerable intravenous dosage of pentoxifylline in AIDS patients does not inhibit lipopolysaccharide-stimulated tumor necrosis factor alpha production. ( Ackermans, M; Endert, E; Heijligenberg, R; Romijn, JA; Sauerwein, HP; Timmer, JG, 1998) |
| "Thus, macrophages from AIDS patients with disseminated MAC infection are deficient in their ability to release TNF alpha, and further inhibition by pentoxifylline may be detrimental." | 1.29 | Pentoxifylline aggravates impairment in tumor necrosis factor-alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection. ( Nedunchezian, D; Sarai, A; Sathe, SS; Tsigler, D, 1994) |
| "Severe weight loss is a common manifestation of advanced infection with the human immunodeficiency virus." | 1.29 | Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. ( Landman, D; Sarai, A; Sathe, SS, 1994) |
| "In this study we treated groups of MAIDS-infected mice with combinations of pentoxifylline, an agent which increases cAMP and inhibits phosphodiesterases, and sodium meclofenamic acid, a PgE2 inhibitor." | 1.29 | Pentoxifylline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS. ( Ambrus, JL; Butsch, J; Chadha, KC; Mathur, N; Munschauer, F; Nakeeb, S; Satchidanand, SK; Stadler, I; Toumbis, C; Vladutiu, A, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (91.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Green, LA | 1 |
| Kim, C | 1 |
| Gupta, SK | 1 |
| Rajashekhar, G | 1 |
| Rehman, J | 1 |
| Clauss, M | 1 |
| Dezube, BJ | 2 |
| Lederman, MM | 1 |
| Spritzler, JG | 1 |
| Chapman, B | 2 |
| Korvick, JA | 2 |
| Flexner, C | 1 |
| Dando, S | 1 |
| Mattiacci, MR | 1 |
| Ahlers, CM | 2 |
| Zhang, L | 1 |
| Sathe, SS | 2 |
| Sarai, A | 2 |
| Tsigler, D | 1 |
| Nedunchezian, D | 1 |
| Landman, D | 1 |
| Pardee, AB | 1 |
| Beckett, LA | 1 |
| Novick, WJ | 1 |
| Chiurco, J | 1 |
| Kasdan, P | 1 |
| Ecto, LT | 1 |
| Santos, J | 1 |
| Márquez, M | 1 |
| Rivero, A | 1 |
| Salgado, F | 1 |
| Stadler, I | 1 |
| Chadha, KC | 1 |
| Nakeeb, S | 1 |
| Toumbis, C | 1 |
| Butsch, J | 1 |
| Mathur, N | 1 |
| Munschauer, F | 1 |
| Vladutiu, A | 1 |
| Satchidanand, SK | 1 |
| Ambrus, JL | 2 |
| Luke, DR | 1 |
| McCreedy, BJ | 1 |
| Sarnoski, TP | 1 |
| Bookout, JB | 1 |
| Johnston, AM | 1 |
| Lell, JE | 1 |
| Wiggan, EB | 1 |
| Bell, N | 1 |
| Limjuco, RA | 1 |
| Guthrie, KI | 1 |
| Paradowski, PT | 1 |
| Zeman, K | 1 |
| Heijligenberg, R | 1 |
| Romijn, JA | 1 |
| Ackermans, M | 1 |
| Endert, E | 1 |
| Timmer, JG | 1 |
| Sauerwein, HP | 1 |
| Smart, T | 1 |
| Lillie, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS[NCT00000646] | Phase 1 | 54 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pentoxifylline and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
[Pentoxifylline].
Topics: Acquired Immunodeficiency Syndrome; Animals; Autoimmune Diseases; Humans; Immunity, Cellular; Killer | 1995 |
2 trials available for pentoxifylline and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; beta 2-Microglobulin; Biopterins; Body Weight; CD4 Lymphocyte Co | 1995 |
Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4-CD8 Ratio; DNA, Viral; Drug Therapy, Combination; Fem | 1993 |
9 other studies available for pentoxifylline and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Pentoxifylline reduces tumor necrosis factor-α and HIV-induced vascular endothelial activation.
Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents; Cells, Cultured; Chemokine CXCL10; Dos | 2012 |
Pentoxifylline aggravates impairment in tumor necrosis factor-alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Colony Count, Microbial; | 1994 |
Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cachexia; Humans; Male; Middle Aged; Pentoxifylline; Pilo | 1994 |
Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; beta 2-Microglobulin; Biopterins; Body Weight; CD4-Positi | 1993 |
[Pentoxifylline in patients with AIDS and oral aphthous ulcers].
Topics: Acquired Immunodeficiency Syndrome; Humans; Pentoxifylline; Stomatitis, Aphthous | 1994 |
Pentoxifylline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Cells, Cultured; Disease Models, Animal; Male; Meclofen | 1994 |
The maximal tolerable intravenous dosage of pentoxifylline in AIDS patients does not inhibit lipopolysaccharide-stimulated tumor necrosis factor alpha production.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug T | 1998 |
Inhibiting TNF to preserve lean body mass.
Topics: Acquired Immunodeficiency Syndrome; Body Mass Index; Humans; Pentoxifylline; Tumor Necrosis Factor-a | 1995 |
Pentoxifylline in treatment of acquired immunodeficiency syndrome?
Topics: Acquired Immunodeficiency Syndrome; Cyclic AMP; Humans; Interferon-alpha; Pentoxifylline | 1992 |